GCM
ABUS icon

Graham Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Graham Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,265
Closed -$60.2K – 1192
2025
Q3 		$60.2K Buy
+13,265
New +$48.7K ﹤0.01% 1188

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Graham Capital Management's ABUS Position: Q4 2025 in Review

Graham Capital Management sold out of Arbutus Biopharma (ABUS) in Q4 2025, closing a stake of 13,265 shares — an estimated $60.2K sold.

Graham Capital Management first reported a position in ABUS in Q3 2025 and held it in 1 quarter. The position peaked at $60.2K in Q3 2025. 172 funds tracked by Wall St. Rank hold ABUS as of Q4 2025.

  • Graham Capital Management reported no remaining Arbutus Biopharma position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 13,265 Arbutus Biopharma shares in Q4 2025, an estimated $60.2K.
  • Graham Capital Management first reported a position in Arbutus Biopharma in Q3 2025 and held it in 1 quarter.
  • Graham Capital Management's Arbutus Biopharma position peaked at $60.2K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.